Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. 2008

R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
Department of Neurology, Edith Wolfson Medical Center, Holon, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. gilad-ar@zahav.net.il

OBJECTIVE To evaluate the efficacy and tolerability of the treatment with valproic acid (VPA) in patients with status epilepticus (SE) or acute repetitive seizures (ARS) comparing it with phenytoin (PHT) treatment. METHODS Patients with SE or ARS were treated in a consecutive manner with either VPA or PHT intravenously. The primary endpoint was defined as clinical seizure cessation; the secondary endpoint was evaluation of drug tolerability. RESULTS Seventy-four adult patients with SE or ARS participated in the study, 49 with VPA i.v. and 25 PHT i.v. In 43 (87.8%) of the VPA patients, the seizures discontinued, and no rescue medication was needed. Similar results were found in the PHT group in which seizures of 22 (88%) patients were well controlled. Side effects were found in 12% of the PHT group, and in none of the VPA group. CONCLUSIONS VPA i.v. seems to be effective and well tolerated in adult patients with SE or ARS.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
January 1983, Advances in neurology,
R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
July 2022, Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery,
R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
June 2012, Epileptic disorders : international epilepsy journal with videotape,
R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
September 1992, Epilepsy research,
R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
April 2019, Continuum (Minneapolis, Minn.),
R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
January 2007, Journal of intensive care medicine,
R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
October 2020, Epilepsy & behavior : E&B,
R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
January 1983, Advances in neurology,
R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
March 2004, No to hattatsu = Brain and development,
R Gilad, and N Izkovitz, and R Dabby, and A Rapoport, and M Sadeh, and B Weller, and Y Lampl
July 2017, Seizure,
Copied contents to your clipboard!